Brexit Effect on Biosimilar


The negative tendency of biosimilars Brexit impact. The hindrance towards the value cutting approach taken by the NHS may be a major setback towards approval and launch of biosimilars in market. With Britain being among foremost clinical preliminary focuses is claimed to ascertain a diminishing within the eagerness of the manufacturers and specialists to try to to any longer preliminaries in Britain. Additionally, Brexit will cause the first rationale of British Biosimilars Association (BBA) to fall back-which went for expanding the use of Biosimilars.


  • No Tariffs or Quotas
  • Life Sciences Investment
  • The

Related Conference of Brexit Effect on Biosimilar

September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 14-15, 2026

5th Global Summit on Pharmaceutical Research

Paris, France
January 26-27, 2027

22nd Annual Meet on Pharmaceutical Sciences

Paris, France
February 15-16, 2027

23rd Annual Congress on Pharmacology and Toxicology

Paris, France
April 08-09, 2027

21st World Drug Delivery Summit

Vienna, Austria
April 27-28, 2027

10th European Biopharma Congress

Paris, France
April 27-28, 2027

19th World Drug Delivery Summit

Paris, France

Brexit Effect on Biosimilar Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in